Rightway raised $155 million to fix pharmacy benefits. Here's what it means for your GLP-1 bill.

The deal

Rightway, a pharmacy benefit manager based in New York, announced on September 24 that it closed a $155 million Series E led by Francisco Partners, with existing backers Thrive Capital and Khosla Ventures also participating. The round brings the company's total funding to $383.75 million since it launched in 2017, building on a 2021 Series C that valued it at $1.1 billion and a $108.75 million Series D in 2024. Rightway says it now manages pharmacy benefits for 45 Fortune 500 companies, close to one in ten of the entire index.

That is a lot of money flowing into the unglamorous middle layer of American healthcare: the pharmacy benefit manager, or PBM, the company your employer hires to negotiate drug prices, build your formulary and process your prescription claims. Co-founder and CEO Jordan Feldman frames the pitch sharply. "The pharmacy supply chain carries a lot of cost that has nothing to do with the medication itself," he said. "Our technology and AI pull costs out of a bloated ecosystem that has failed to be efficient and transparent." Francisco Partners co-president Ezra Perlman described the investment case in similar terms, saying Rightway has "a differentiated model that combines aligned incentives, technology, and clinical expertise to help employers better manage pharmacy costs while improving the member experience."

Why this round is really a GLP-1 bet

Read past the funding headline and the story is narrower and more specific: this is money chasing the GLP-1 supply chain. Employer spending on GLP-1 drugs like Ozempic, Wegovy and Zepbound doubled in a single year, rising from $11 to $24 per member per month, and the drug class now accounts for more than one in ten prescription claims at large employers, according to Espresa's 2026 benchmark report on workplace benefits. For a company whose entire business is managing what employers spend on prescriptions, that is the whole ballgame. Traditional PBMs have historically made money on the spread between what a manufacturer charges and what they bill a plan, plus rebates they often keep part of. Rightway's answer is a model it calls SureSpend, built from two pieces: a Precision Pricing Guarantee that caps an employer's total pharmacy spend, and a Zero-Markup Wrap that covers GLP-1s and other high-cost excluded drugs at net cost, with the company saying it passes through 100% of manufacturer rebates rather than keeping a cut.

What transparent pricing has and hasn't fixed

The structural change here is real. A PBM that publicly commits to zero markup and full rebate pass-through, and that doesn't own its own pharmacies, is a genuinely different animal from the legacy PBMs that dominate the market and have faced years of scrutiny over hidden fees and self-dealing. But transparency in pricing is not the same as a guaranteed lower bill, and health-policy researchers have been clear about the gap. Rebate arrangements between PBMs and manufacturers can still reward formularies that favor a higher-priced drug over a cheaper, equally effective one, because the rebate on the expensive drug is worth more even after it's passed through. Publishing the math doesn't remove that incentive, it just makes the math visible. GLP-1 economics remain brutal regardless of which PBM sits in the middle: net costs for an active user typically run somewhere between $400 and $700 a month even after rebates, which is why so many employers are capping who qualifies for coverage rather than opening the floodgates.

Does the money reach your paycheck

Here is the part the press release does not spell out, and it matters more than the funding figure. Rightway sells to employers, not to you. Every dollar this deal claims to save gets negotiated at the employer level first, and what happens next, whether it shows up as a lower copay, a wider formulary or simply a smaller premium increase next year, is entirely up to how your specific company structures its plan. A PBM passing through 100% of rebates is a genuine improvement over one that quietly keeps a slice, but full pass-through describes where the money goes on the employer's ledger, not what lands in your pocket at the pharmacy counter. That gap is exactly why people have started microdosing GLP-1 drugs off-label to make them affordable: official coverage, even under a reformed PBM, still leaves plenty of people priced out or capped out.

Our take

Rightway raising $155 million is a real signal that investors think there is money to be made fixing a genuinely broken layer of the drug supply chain, and its model addresses a documented problem: PBM opacity and misaligned rebate incentives. That is worth crediting. But the entire value proposition depends on employers actually passing savings to workers, something no funding round can guarantee and no press release measures. If your company adopts a PBM like this one, the number that matters is not $155 million. It's the number on your next pharmacy receipt, compared with the one before.

Health Trend Wire holds no position in Rightway and was not paid for this article. This is general information, not medical or financial advice.